Transgenic animal model of mood disorders

Abstract

A non-human transgenic animal having a polynucleotide encoding a PTN polypeptide, which polynucleotide is operably linked to a promoter, wherein said transgenic animal has greater than wild-type expression of the PTN polypeptide in at least one brain region, as well as related vectors, methods of producing transgenic animals, in vitro and in vivo screening methods for potential therapeutic agents, and methods for treating and diagnosing neuropsychiatric illnesses, particularly anxiety and depression, are disclosed.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This is a continuation of U.S. patent application Ser. No. 14 / 386,319, filed Sep. 18, 2014, which is the U.S. National Stage of International Application No. PCT / EP2013 / 055253, filed Mar. 14, 2013, which was published in English under PCT Article 21(2), which in turn claims the benefit of GB Application No. 1204816.1, filed Mar. 19, 2012, all of which are incorporated herein in its entirety.FIELD OF THE INVENTION[0002]The present invention relates to a marker for psychiatric illness, particularly mood disorders such as Major Depressive Disorder (MDD), Anxiety and Bipolar Disorder (BD), to animal models utilising the marker, to methods of screening for agents that affect the marker and which may have therapeutic potential, and to uses for treatment based on down-regulation of the marker expression and / or antagonism of its activity.BACKGROUND TO THE INVENTION[0003]Psychiatric disorders such as major depression, anxiety or bipolar disorder a...

AI Technical Summary

Benefits of technology

The present invention provides a non-human transgenic animal with increased expression of a polynucleotide encoding a PTN polypeptide in at least one brain region. The transgenic animal exhibits one or more anxious and / or depressive-related behaviours, such as reduced time spent in open arms of an elevated plus maze, reduced time in central area in an open-field test, reduced time in light in a light-dark box test, increased latency to feed in a Novelty Suppressed Feeding Test, increased immobility time in tail suspension test, and reduced sucrose intake in sucrose intake task. The use of a more neuronal-specific promoter, the Thy promoter, is believed to contribute to the anxiety and depression-related behavior of the transgenic animal. The PTN transgenic animal may provide a better animal model of mood disorders and a more specific tool for studying the disease.

Problems solved by technology

Furthermore, these illnesses do not develop because of the alteration of one single gene but more likely due to changes in a group of genes, which makes them multi-factor illnesses.

Also, depression is associated with considerable morbidity and excess mortality (Sullivan et al., 2000; Belmaker and Agam, 2008).

The resulting cost to the US economy is estimated to be in the range of US $100 billion per year.

But in spite of these considerable financial incentives and the public health importance of treating depression, there is an absence of conceptually novel antidepressants on the market, reflecting the difficulties encountered in the development of new treatment strategies for this common and complex disorder.

Although these mono amine-based agents are potent antidepressants, and alterations in central monoamine function might contribute marginally to genetic vulnerability, the cause of depression is far from being a simple deficiency of central monoamines.

Animal models are widely used to study the neurobiological mechanisms of depression and anxiety but mouse models that mimic the full phenotypic spectrum of a psychiatric disorder, such as major depression, are virtually impossible.

However, it is difficult to prepare a model reflecting a human disease having a mechanism of development which is unknown, such as depression (Krishnan and Nestler, 2010).

A significant difficulty remains the translation of genetic association studies into models that are effective for evaluating the efficacy of candidate therapeutic compounds.

In particular, the complexity of the disorder means that it is not normally possible to predict whether a genetic alteration associated with the disorder has a causal role and will produce behavioural changes of relevance to depression and / or anxiety.

Images